BR9612275A - Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e aumentar a taxa e a extensão do crescimento da produção do leite e lã ou para tratar doenças e uso de um composto - Google Patents

Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e aumentar a taxa e a extensão do crescimento da produção do leite e lã ou para tratar doenças e uso de um composto

Info

Publication number: BR9612275A
Authority: BR; Brazil
Prior art keywords: compound; growth; pituitary; stimulate; milk
Prior art date: 1995-12-22

Application number

BR9612275A

Other languages

English (en)

Inventor

Thomas Kruse Hansen

Jesper Lau

Behrend Friedrich Lundt

Bernd Peschke

Michael Ankersen

Kjeld Madsen

Brett Watson

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-22

Filing date

1996-12-16

Publication date

1999-07-13

1996-12-16 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1999-07-13 Publication of BR9612275A publication Critical patent/BR9612275A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J19/00—Character- or line-spacing mechanisms
- B41J19/18—Character-spacing or back-spacing mechanisms; Carriage return or release devices therefor
- B41J19/20—Positive-feed character-spacing mechanisms
- B41J19/202—Drive control means for carriage movement
- B41J19/205—Position or speed detectors therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

BR9612275A 1995-12-22 1996-12-16 Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e aumentar a taxa e a extensão do crescimento da produção do leite e lã ou para tratar doenças e uso de um composto BR9612275A (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
DK146295		1995-12-22
DK69896		1996-06-25
US2206296P	1996-07-22	1996-07-22
DK81296		1996-07-24
DK124896		1996-11-06
PCT/DK1996/000529 WO1997023508A1 (en)	1995-12-22	1996-12-16	Compounds with growth hormone releasing properties
US08/769,020 US5977178A (en)	1995-12-22	1996-12-18	Compounds with growth hormone releasing properties

Publications (1)

Publication Number	Publication Date
BR9612275A true BR9612275A (pt)	1999-07-13

Family

ID=27545172

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9612275A BR9612275A (pt)	1995-12-22	1996-12-16	Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e aumentar a taxa e a extensão do crescimento da produção do leite e lã ou para tratar doenças e uso de um composto

Country Status (18)

Country	Link
US (4)	US5977178A (pt)
EP (1)	EP0869974B1 (pt)
JP (2)	JP3701686B2 (pt)
CN (1)	CN1211991A (pt)
AT (1)	ATE424412T1 (pt)
AU (1)	AU715856B2 (pt)
BR (1)	BR9612275A (pt)
CA (1)	CA2239711A1 (pt)
CZ (1)	CZ195098A3 (pt)
DE (1)	DE69637855D1 (pt)
ES (1)	ES2323159T3 (pt)
HU (1)	HUP9802580A3 (pt)
IL (1)	IL124702A0 (pt)
MX (1)	MX9804830A (pt)
NO (1)	NO982872L (pt)
PL (1)	PL327227A1 (pt)
TW (1)	TW480248B (pt)
WO (1)	WO1997023508A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU705744B2 (en)	1995-01-27	1999-06-03	Sapphire Therapeutics, Inc.	Compounds with growth hormone releasing properties
EP0869974B1 (en) *	1995-12-22	2009-03-04	Novo Nordisk A/S	Compounds with growth hormone releasing properties
JP4425992B2 (ja) *	1996-07-22	2010-03-03	サファイアセラピューティクス，インコーポレイティド	成長ホルモン放出特性を有する化合物
US6117841A (en) *	1997-05-30	2000-09-12	Warner-Lambert Company	Substituted peptidylamine calcium channel blockers
US6127341A (en) *	1997-06-20	2000-10-03	Novo Nordisk A/S	Compounds with growth hormone releasing properties
WO1998058950A1 (en)	1997-06-20	1998-12-30	Novo Nordisk A/S	Compounds with growth hormone releasing properties
UA64751C2 (uk)	1997-06-25	2004-03-15	Пфайзер Продактс Інк.	Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
KR20010034198A (ko)	1998-01-16	2001-04-25	한센 핀 베네드	성장 호르몬 방출성을 가지는 화합물
US6083908A (en) *	1998-01-16	2000-07-04	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US6281247B1 (en)	1998-03-03	2001-08-28	Novo Nordisk A/S	Salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide
AU3247899A (en) *	1998-03-03	1999-09-20	Novo Nordisk A/S	New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide
US6784158B1 (en) *	1998-06-09	2004-08-31	Novo Nordisk A/S	Method for preparing a compound with growth hormone releasing properties
WO1999067235A1 (en) *	1998-06-25	1999-12-29	Sumitomo Pharmaceuticals Co., Ltd.	Five-membered ring compounds
PL199853B1 (pl) *	1998-06-30	2008-11-28	Novo Nordisk As	Związek o właściwościach uwalniania hormonu wzrostu, kompozycja zawierająca ten związek oraz jego zastosowanie do stymulowania uwalniania hormonu wzrostu
US6919315B1 (en)	1998-06-30	2005-07-19	Novo Nordisk A/S	Compounds with growth hormone releasing properties
JP4481502B2 (ja) *	1998-11-03	2010-06-16	サファイアセラピューティクス，インコーポレイティド	成長ホルモン放出特性を有する化合物
US6566337B1 (en)	1998-11-03	2003-05-20	Novo Nordisk A/S	Compounds with growth hormone releasing properties
KR100699404B1 (ko)	1999-02-18	2007-03-23	가켄 세야쿠 가부시키가이샤	성장 호르몬 분비촉진제로서의 신규 아미드 유도체
US6518292B1 (en) *	1999-03-12	2003-02-11	Bristol-Myers Squibb Co.	Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
AU3841500A (en) *	1999-04-22	2000-11-10	Sankyo Company Limited	Resin-bearing ketoamides and process for the preparation thereof
JP2003507376A (ja) *	1999-08-18	2003-02-25	シエーリングアクチエンゲゼルシャフト	神経活性を示すピペリジンおよびピロリジン誘導体
US20010020012A1 (en) *	2000-02-01	2001-09-06	Andersen Maibritt Bansholm	Use of compounds for the regulation of food intake
ATE446758T1 (de)	2000-05-31	2009-11-15	Pfizer Prod Inc	Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
US7425537B2 (en) *	2000-08-22	2008-09-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	SH2 domain binding inhibitors
AU2003217676B2 (en)	2002-02-22	2009-06-11	Takeda Pharmaceutical Company Limited	Active agent delivery systems and methods for protecting and administering active agents
AU2003265398A1 (en)	2002-08-09	2004-02-25	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
MY139563A (en) *	2002-09-04	2009-10-30	Bristol Myers Squibb Co	Heterocyclic aromatic compounds useful as growth hormone secretagogues
EP1407779A1 (en)	2002-10-10	2004-04-14	Gastrotech A/S	Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (en)	2003-08-08	2005-02-17	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions and methods of use
WO2005027913A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005097261A1 (en) *	2004-03-30	2005-10-20	Sapphire Therapeutics, Inc.	Method of reducing c-reactive protein using growth hormone secretagogues
KR101380200B1 (ko) *	2004-08-12	2014-04-01	헬신 세라퓨틱스 (유.에스.) 인크.	성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을촉진하는 방법
EP1757290A1 (en)	2005-08-16	2007-02-28	Zentaris GmbH	Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
CU23558A1 (es) *	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
DK2118123T3 (en)	2007-01-31	2016-01-25	Dana Farber Cancer Inst Inc	Stabilized p53 peptides and uses thereof
ES2604943T3 (es)	2007-02-09	2017-03-10	Ocera Therapeutics, Inc.	Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
CN101686966A (zh) *	2007-02-13	2010-03-31	赫尔辛医疗（美国）有限公司	使用生长激素促分泌素治疗细胞增生疾病的方法
EP3159352B1 (en)	2007-03-28	2023-08-02	President and Fellows of Harvard College	Stitched polypeptides
TWI429436B (zh) *	2007-04-10	2014-03-11	Helsinn Therapeutics Us Inc	使用生長激素促泌素治療或預防嘔吐之方法
WO2010009389A1 (en) *	2008-07-17	2010-01-21	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Use of targeted nitroxide agents in preventing, mitigating and treating radiation injury
WO2010009327A1 (en)	2008-07-17	2010-01-21	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Compounds for the treatment of pathologies associated with aging and degenerative disorders
UA105657C2 (uk)	2009-02-27	2014-06-10	Хелсінн Терапьютікс (Ю.Ес.), Інк.	Поліпшені способи лікування мігрені на основі анамореліну
US8748369B2 (en)	2009-06-05	2014-06-10	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Use of targeted nitroxide agents in bone healing
SI2603600T1 (sl)	2010-08-13	2019-04-30	Aileron Therapeutics, Inc.	Peptidomimetični makrocikli
EP2431035A1 (en)	2010-09-16	2012-03-21	Æterna Zentaris GmbH	Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
PT3409278T (pt)	2011-07-21	2020-12-18	Sumitomo Dainippon Pharma Oncology Inc	Inibidores de proteína cinase heterocíclicos
EP2768518A4 (en)	2011-10-18	2015-05-27	Aileron Therapeutics Inc	PEPTIDOMIMETIC MACROCYCLES
WO2013123267A1 (en)	2012-02-15	2013-08-22	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en)	2012-02-15	2015-01-06	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
AU2013337388B2 (en)	2012-11-01	2018-08-02	Aileron Therapeutics, Inc.	Disubstituted amino acids and methods of preparation and use thereof
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
MX2017003797A (es)	2014-09-24	2017-06-15	Aileron Therapeutics Inc	Macrociclos peptidomimeticos y usos de los mismos.
CN107614003A (zh)	2015-03-20	2018-01-19	艾瑞朗医疗公司	拟肽大环化合物及其用途
WO2017075535A1 (en)	2015-10-28	2017-05-04	Oxeia Biopharmaceuticals, Inc.	Methods of treating neurodegenerative conditions
CA3127502A1 (en)	2019-02-12	2020-08-20	Sumitomo Dainippon Pharma Oncology, Inc.	Formulations comprising heterocyclic protein kinase inhibitors
CN112724052B (zh) *	2021-01-21	2021-09-07	南京艾美斐生物医药科技有限公司	一种gpr101蛋白受体抑制剂及其制备和应用
CN116947658B (zh) *	2023-07-28	2025-10-28	南通华祥医药科技有限公司	一种1-氨基-2-甲基-2-丙醇的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0663834A4 (en) *	1992-09-25	1996-01-24	Smithkline Beecham Corp	GROWTH HORMONE RELEASING PEPTIDES.
NZ277486A (en) *	1993-12-23	1997-03-24	Novo Nordisk As	Synthetic peptides with growth hormone releasing properties
DE4421052A1 (de) *	1994-06-17	1995-12-21	Basf Ag	Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5798337A (en) *	1994-11-16	1998-08-25	Genentech, Inc.	Low molecular weight peptidomimetic growth hormone secretagogues
AU705744B2 (en) *	1995-01-27	1999-06-03	Sapphire Therapeutics, Inc.	Compounds with growth hormone releasing properties
EP0869974B1 (en) *	1995-12-22	2009-03-04	Novo Nordisk A/S	Compounds with growth hormone releasing properties

1996
- 1996-12-16 EP EP96941591A patent/EP0869974B1/en not_active Expired - Lifetime
- 1996-12-16 CZ CZ981950A patent/CZ195098A3/cs unknown
- 1996-12-16 IL IL12470296A patent/IL124702A0/xx unknown
- 1996-12-16 HU HU9802580A patent/HUP9802580A3/hu unknown
- 1996-12-16 PL PL96327227A patent/PL327227A1/xx unknown
- 1996-12-16 JP JP52323097A patent/JP3701686B2/ja not_active Expired - Fee Related
- 1996-12-16 ES ES96941591T patent/ES2323159T3/es not_active Expired - Lifetime
- 1996-12-16 AT AT96941591T patent/ATE424412T1/de not_active IP Right Cessation
- 1996-12-16 BR BR9612275A patent/BR9612275A/pt not_active IP Right Cessation
- 1996-12-16 AU AU10929/97A patent/AU715856B2/en not_active Ceased
- 1996-12-16 CA CA002239711A patent/CA2239711A1/en not_active Abandoned
- 1996-12-16 CN CN96199770A patent/CN1211991A/zh active Pending
- 1996-12-16 WO PCT/DK1996/000529 patent/WO1997023508A1/en not_active Ceased
- 1996-12-16 DE DE69637855T patent/DE69637855D1/de not_active Expired - Lifetime
- 1996-12-18 US US08/769,020 patent/US5977178A/en not_active Expired - Lifetime
1997
- 1997-01-08 TW TW086100130A patent/TW480248B/zh not_active IP Right Cessation
1998
- 1998-06-16 MX MX9804830A patent/MX9804830A/es not_active IP Right Cessation
- 1998-06-19 NO NO982872A patent/NO982872L/no not_active Application Discontinuation
- 1998-12-21 US US09/218,686 patent/US6127391A/en not_active Expired - Lifetime
1999
- 1999-11-19 JP JP32892999A patent/JP4130519B2/ja not_active Expired - Fee Related
2000
- 2000-03-23 US US09/534,135 patent/US6555570B2/en not_active Expired - Fee Related
2002
- 2002-02-05 US US10/067,895 patent/US6939880B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6127391A (en)	2000-10-03
AU1092997A (en)	1997-07-17
DE69637855D1 (de)	2009-04-16
PL327227A1 (en)	1998-12-07
EP0869974B1 (en)	2009-03-04
JP4130519B2 (ja)	2008-08-06
US20030040483A1 (en)	2003-02-27
TW480248B (en)	2002-03-21
IL124702A0 (en)	1998-12-06
HUP9802580A3 (en)	1999-03-29
US5977178A (en)	1999-11-02
NO982872L (no)	1998-08-21
MX9804830A (es)	1998-09-30
US6555570B2 (en)	2003-04-29
ATE424412T1 (de)	2009-03-15
JPH11501054A (ja)	1999-01-26
JP3701686B2 (ja)	2005-10-05
ES2323159T3 (es)	2009-07-07
CA2239711A1 (en)	1997-07-03
US6939880B2 (en)	2005-09-06
AU715856B2 (en)	2000-02-10
US20030055261A1 (en)	2003-03-20
HUP9802580A2 (hu)	1999-02-01
JP2000143613A (ja)	2000-05-26
WO1997023508A1 (en)	1997-07-03
EP0869974A1 (en)	1998-10-14
CZ195098A3 (cs)	1998-10-14
JPH11209336A (ja)	1999-08-03
CN1211991A (zh)	1999-03-24
NO982872D0 (no)	1998-06-19

Publication	Publication Date	Title
BR9612275A (pt)	1999-07-13	Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e aumentar a taxa e a extensão do crescimento da produção do leite e lã ou para tratar doenças e uso de um composto
NO962665L (no)	1996-08-23	Forbindelser med veksthormonfrigjörende egenskaper
KR960007545A (ko)	1996-03-22	합성 흥분성 아미노산
EA199800563A1 (ru)	1998-12-24	Антагонисты гормона, высвобождающего гонадотропин
MY133647A (en)	2007-11-30	Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
EP1184370A3 (en)	2002-03-27	Compounds with growth hormone releasing properties
FR2677982B1 (fr)	1993-09-24	Composes polyfluoroalkylthiopoly(ethylimidazolium), procede de preparation et leur utilisation comme agents biocides.
BG96513A (bg)	1993-12-24	Заместени 4-фенил-4-пиперидинкарбоксамиди с локален обезболяващ и болкоуспокояващ ефект и метод за тяхното получаване
WO2000013650A3 (en)	2000-06-02	Neuroprotection
BR9708854A (pt)	1999-08-03	Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e para aumentar a taxa e grau de crescimento de animais e uso de um composto
FI903571A0 (fi)	1990-07-13	Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
NO20014240D0 (no)	2001-08-31	C16-umettede FP-selektive prostaglandinanaloger
EP0328203A3 (en)	1990-03-14	[5(6) (1H-azole-1-ylmethyl)benzimidazole] carbamates
KR970706251A (ko)	1997-11-03	항종양제 및 항바이러스제로서의 비스-(2-할로에틸)아미노페닐 치환된 디스타마이신 유도체(Bis-(2-haloethyl)aminophenyl substituted distamycin derivatives as antitumor and antiviral agents)
MXPA02000242A (es)	2004-09-10	Analogos de 2-aminoindano.
BR9906975A (pt)	2000-10-17	Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
WO2001002340A3 (en)	2001-06-14	Novel aminoindanes
EA199800368A1 (ru)	1998-12-24	Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов
DE69619530D1 (de)	2002-04-04	Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
ES2139934T3 (es)	2000-02-16	Procedimiento mejorado para preparar derivados de cadena lateral de ciclohexapeptidil lipopeptidos.
KR940000443A (ko)	1994-01-03	피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드
FR2737409B1 (fr)	1997-10-24	Nouvelles utilisations de diamines alticycliques
RU94017615A (ru)	1997-02-27	Способ получения пептида
RU95109103A (ru)	1996-12-20	Производные 1,2,4-дитиазолия в виде йодида, смесь их изомеров или отдельные изомеры, исходные продукты для их получения и средство для борьбы с вредителями на их основе
EP0120304A3 (en)	1984-12-19	Substituted 4,10-dihydro-10-oxothieno benzoxepins and intermediates thereof, a process for their preparation and their use as medicaments

Legal Events

Date	Code	Title	Description
2006-12-19	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A E 10A ANUIDADES.
2011-12-06	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1876 DE 19/12/2006.